Prospective Study on Low-Dose Mifepristone for the Treatment of Leiomyoma: A Hospital Based Study

  • Sabita Sukla Das Associate Professor, Dept. of Obstetrics & Gynaecology, Pataliputra Medical College, Jharkhand.
Keywords: Fibroid uterus, Mifepristone, Medical treatment, Hemoglobin

Abstract

Background: Fibroid or myoma is the commonest reported tumor of uterus, and is one of the important reasons for hysterectomy in our setting. Medical Management of fibroid uterus can be done by Mifepristone, a progesterone antagonist. This study was commenced to study the effect of mifepristone on the symptoms and size of fibroids, especially using a low-dose regimen for 6 months. In addition, any symptomatic improvement of menorrhagia and dysmenorrhea was also studied. Materials & Methods: The study was designed as an observational prospective study done on women diagnosed with uterine fibroids attending OPD of Dept. of Obstetrics & Gynaecology, Pataliputra Medical College, Jharkhand. A total of 48 patients were enrolled in the study. Out pf 48, only 36 patients completed our study.  50 mg of mifepristone weekly used, and patient assessed at 1 and 6 month. They were a follow up period of 3 months after stopping the drug to observe the changes in menstrual pattern, fibroid volume, hemoglobin and liver function tests. Results: Majority of the study population comprised of perimenopausal women, i.e., 36–45 years (48 %). Fifty percent of the patients were Para 2 and belonged to the perimenopausal age-group (18 out of 36). The dominant presenting symptom was menorrhagia associated with dysmenorrhea and pelvic pain. After 6 months of treatment with mifepristone, the mean fibroid volume reduced from 204.33 to 113.16 cm3 (n = 33), and the percentage mean volume reduction of the fibroid in the study population was 44.57 %. Immediate reduction in bleeding PV was observed in 100 %, and 88.89 % (32/36) patients attained amenorrhea. The mean hemoglobin increased from 9.18 to 10.82 g/dl. Conclusion: To conclude, 6 months therapy with 50 mg of mifepristone given weekly is efficacious and acceptable for the treatment of symptomatic leiomyoma, especially in a select group of patients.

 

 

Downloads

Download data is not yet available.

References

1. Breech LL, Rock JA. Leiomyomata uteri and myomectomy. In: Rock JA, Jones III HW, editors. Te Linde’s operative gynecology. 10th ed. New Delhi: Wolters Kluwer Pvt Ltd; 2010. p. 687–726.
2. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36:433–45.
3. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76(2):513–7.
4. Carbonell JL, Acosta R, Perez Y, et al. Safety of 10 mg versus 5 mg of Mifepristone during 9 months for the treatment of uterine fibroids. Double-blind randomized clinical trial. Int J Women’s Health. 2013;5:115–24.
5. Bagaria M, Suneja A, Vaid NB, et al. Low-dose Mifepristone in treatment of uterine leiomyoma: a randomized double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009;49:77–83.
6. Mukherjee S, Chakraborty S. A study evaluating the effect of Mifepristone (RU 486) for the treatment of leiomyomata uteri. Niger Med J. 2011;52(3):150–2.
7. Fiscella K, Eisinger SH, Meldrum S, et al. Effect of Mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1381–7.
8. Kulshrestha V, Kriplani L, Agarwal N, et al. Low dose Mifepristone in medical management of uterine leiomyoma—an experience from a tertiary care hospital from north India. Indian J Med Res. 2013;137:1154–62.
9. Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose Mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12(3):227–33.
Published
2018-03-21
How to Cite
1.
Das S. Prospective Study on Low-Dose Mifepristone for the Treatment of Leiomyoma: A Hospital Based Study. IABCR [Internet]. 21Mar.2018 [cited 21Sep.2018];4(1):104-6. Available from: https://iabcr.org/index.php/iabcr/article/view/280